Ketotifen (English Wikipedia)

Nelson WL (2008). "Antihistamines and Related Antiallergic and Antiulcer Agents". In Lemke TL, Williams DA (eds.). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1019–. ISBN 978-0-7817-6879-5.
Alagarsamy V (16 June 2012). "Antihistamines". Textbook of Medicinal Chemistry Vol II - E-Book. Elsevier Health Sciences. pp. 38–. ISBN 978-81-312-3259-0.
Drews J (6 December 2012). "Substances with an Antialergic Effect". Immunopharmacology: Principles and Perspectives. Springer Science & Business Media. pp. 282–. ISBN 978-3-642-75561-3.
Alapi EM, Fischer J (2006). "Table of Selected Analogue Classes". In Fischer J, Ganellin CR (eds.). Analogue-based Drug Discovery. John Wiley & Sons. p. 548. ISBN 978-3-527-60749-5. Archived from the original on 10 January 2023. Retrieved 1 August 2020.

canada.ca

health-products.canada.ca

"Zaditen Product information". Health Canada. 22 October 2009. Archived from the original on 10 March 2024. Retrieved 10 March 2024.
"Zaditor Product information". Health Canada. 22 October 2009. Archived from the original on 10 March 2024. Retrieved 10 March 2024.

chestnet.org

journal.chestnet.org

MacDonald G (1982). "An Overview of Ketotifen". Chest. 82 (1 Suppl): 30s – 32s. doi:10.1378/chest.82.1.30S. PMID 6806019. Archived from the original on 13 April 2024. Retrieved 13 April 2024.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Ketotifen Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Archived from the original on 4 June 2023. Retrieved 30 August 2024.

clinicaltrials.gov

classic.clinicaltrials.gov

"A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Norketotifen (NKT) in the Treatment of Acute Uncomplicated Influenza-like Illness (ILI)". 25 January 2023. Archived from the original on 13 April 2024. Retrieved 13 April 2024.

doi.org

Grant SM, Goa KL, Fitton A, Sorkin EM (September 1990). "Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders". Drugs. 40 (3): 412–448. doi:10.2165/00003495-199040030-00006. PMID 2226222. S2CID 242916740.
Ono J, Toshida H (July 2022). "Use of Ketotifen Fumarate-Eluting Daily Disposable Soft Contact Lens in Management of Ocular Allergy: Literature Review and Report of Two Cases". Cureus. 14 (7): e27093. doi:10.7759/cureus.27093. PMC 9391663. PMID 36000122.
García-Martín E, Canto G, Agúndez JA (November 2013). "Metabolic considerations of drugs in the treatment of allergic diseases". Expert Opin Drug Metab Toxicol. 9 (11): 1437–52. doi:10.1517/17425255.2013.823400. PMID 23902458. S2CID 30634949.
Dou XY, Zhang W (2023). "Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis". Int J Ophthalmol. 16 (2): 286–292. doi:10.18240/ijo.2023.02.17. PMC 9922628. PMID 36816214.
Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. (October 2009). "EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria". Allergy. 64 (10): 1427–1443. doi:10.1111/j.1398-9995.2009.02178.x. PMID 19772513. S2CID 14587946.
Sokol KC, Amar NK, Starkey J, Grant JA (December 2013). "Ketotifen in the management of chronic urticaria: resurrection of an old drug". Annals of Allergy, Asthma & Immunology. 111 (6): 433–436. doi:10.1016/j.anai.2013.10.003. PMC 4309375. PMID 24267353.
Shawky RM, Seifeldin NS (2015). "The relation between antihistamine medication during early pregnancy & birth defects". Egyptian Journal of Medical Human Genetics. 16 (4): 287–90. doi:10.1016/j.ejmhg.2015.04.003.
Zuberbier T (January 2012). "A Summary of the New International EAACI/GA(2)LEN/EDF/WAO Guidelines in Urticaria". The World Allergy Organization Journal. 5 (Suppl 1): S1 – S5. doi:10.1186/1939-4551-5-S1-S1. PMC 3488932. PMID 23282889.
Frieri M (June 2018). "Mast Cell Activation Syndrome". Clin Rev Allergy Immunol. 54 (3): 353–365. doi:10.1007/s12016-015-8487-6. PMID 25944644. S2CID 5723622.
Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, et al. (2018). "The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets". Front Immunol. 9: 1873. doi:10.3389/fimmu.2018.01873. PMC 6099187. PMID 30150993.
Simons FE, Simons KJ (December 2011). "Histamine and H1-antihistamines: celebrating a century of progress". J Allergy Clin Immunol. 128 (6): 1139–1150.e4. doi:10.1016/j.jaci.2011.09.005. PMID 22035879.
Linton S, Hossenbaccus L, Ellis AK (October 2023). "Evidence-based use of antihistamines for treatment of allergic conditions". Ann Allergy Asthma Immunol. 131 (4): 412–420. doi:10.1016/j.anai.2023.07.019. PMID 37517656.
Ormerod AD (November 1994). "Urticaria. Recognition, causes and treatment". Drugs. 48 (5): 717–30. doi:10.2165/00003495-199448050-00006. PMID 7530629.
Sastre E, Caracuel L, Xavier FE, Balfagón G, Blanco-Rivero J (2013). "Opposite effect of mast cell stabilizers ketotifen and tranilast on the vasoconstrictor response to electrical field stimulation in rat mesenteric artery". PLOS ONE. 8 (8): e73232. Bibcode:2013PLoSO...873232S. doi:10.1371/journal.pone.0073232. PMC 3748149. PMID 23977380.
Suzuki Y, Inoue T, Ra C (14 February 2012). "Calcium Signaling in Mast Cells: Focusing on L-Type Calcium Channels". Calcium Signaling. Advances in Experimental Medicine and Biology. Vol. 740. pp. 955–977. doi:10.1007/978-94-007-2888-2_44. ISBN 978-94-007-2888-2. PMID 22453979.
Holowka D, Wilkes M, Stefan C, Baird B (April 2016). "Roles for Ca2+ mobilization and its regulation in mast cell functions: recent progress". Biochem Soc Trans. 44 (2): 505–9. doi:10.1042/BST20150273. PMC 5293407. PMID 27068962.
El-Alali EA, Abukhiran IM, Alhmoud TZ (July 2021). "Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review". BMC Gastroenterology. 21 (1): 279. doi:10.1186/s12876-021-01854-x. PMC 8265096. PMID 34238222.
MacDonald G (1982). "An Overview of Ketotifen". Chest. 82 (1 Suppl): 30s – 32s. doi:10.1378/chest.82.1.30S. PMID 6806019. Archived from the original on 17 July 2024. Retrieved 17 July 2024.
Markham A, Goa KL (1996). "Ketotifen". Clinical Immunotherapeutics. 5 (5): 400–411. doi:10.1007/BF03259336. Archived from the original on 6 August 2024. Retrieved 17 July 2024.
Schwarzer G, Bassler D, Mitra A, Ducharme FM, Forster J (2004). "Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children". Cochrane Database Syst Rev. 2004 (1): CD001384. doi:10.1002/14651858.CD001384.pub2. PMC 8406918. PMID 14973969.
Grahnén A, Lönnebo A, Beck O, Eckernäs SA, Dahlström B, Lindström B (May 1992). "Pharmacokinetics of ketotifen after oral administration to healthy male subjects". Biopharmaceutics & Drug Disposition. 13 (4): 255–262. doi:10.1002/bdd.2510130404. PMID 1600111. S2CID 72293850.
Zhu TH, Zou G, Ding SJ, Li TT, Zhu LB, Wang JZ, et al. (2019). "Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis". J Pain Res. 12: 1359–1369. doi:10.2147/JPR.S195909. PMC 6500880. PMID 31118754. Ketotifen has a stronger effect on stabilizing MCs than sodium cromoglycate. This drug has antihistamine activity and is also a functional leukotriene antagonist
Bäck M (2016). "Leukotrienes". Compendium of Inflammatory Diseases. pp. 849–857. doi:10.1007/978-3-7643-8550-7_105. ISBN 978-3-7643-8530-9.
Sasaki F, Yokomizo T (August 2019). "The leukotriene receptors as therapeutic targets of inflammatory diseases". Int Immunol. 31 (9): 607–615. doi:10.1093/intimm/dxz044. PMID 31135881.
Mostafa GA, Bakheit A, AlMasoud N, AlRabiah H (April 2021). "Charge Transfer Complexes of Ketotifen with 2,3-Dichloro-5,6-dicyano-p-benzoquinone and 7,7,8,8-Tetracyanoquodimethane: Spectroscopic Characterization Studies". Molecules. 26 (7): 2039. doi:10.3390/molecules26072039. PMC 8038309. PMID 33918481.
Omori K, Kotera J (February 2007). "Overview of PDEs and their regulation". Circ Res. 100 (3): 309–27. doi:10.1161/01.RES.0000256354.95791.f1. PMID 17307970.
Feneck R (1 December 2007). "Phosphodiesterase inhibitors and the cardiovascular system". Continuing Education in Anaesthesia Critical Care & Pain. 7 (6): 203–207. doi:10.1093/bjaceaccp/mkm039.
Baselga E, Torrelo A (2008). "Inflammatory and Purpuric Eruptions". Neonatal Dermatology. pp. 311–342. doi:10.1016/B978-1-4160-3432-2.50022-4. ISBN 978-1-4160-3432-2.
Chaplin S, Scadding G (2011). "Antihistamines: Their properties and use in hay fever". Prescriber. 22 (10): 29–31. doi:10.1002/psb.758. Some antihistamines should not be used in people with acute porphyria. Those believed to be safe are chlorphenamine, desloratadine, fexofenadine, ketotifen (Zaditen), loratadine and promethazine (Phenergan)
Yokoyama H, Iinuma K (18 November 2012) [May 1996]. "Histamine and Seizures". CNS Drugs. 5 (5): 321–330. doi:10.2165/00023210-199605050-00002. PMID 26071045.
Waterfield J (29 September 2013). "Antihistamines: Mode of action, prescribing rationale and uses". Nurse Prescribing. 7 (4): 166–170. doi:10.12968/npre.2009.7.4.41711.
Chaplin S, Scadding G (13 June 2011). "Antihistamines: Their properties and use in hay fever". Prescriber. 22 (10): 29–31. doi:10.1002/psb.758.
Jue TL, Storm AC, Naveed M, Fishman DS, Qumseya BJ, McRee AJ, et al. (2021). "ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction". Gastrointestinal Endoscopy. 93 (2): 309–322.e4. doi:10.1016/j.gie.2020.07.063. PMID 33168194.
Shim K (2019). "Endoscopic Management for Pyloric Stricture and Gastric Outlet Obstruction: Dilation and Stenting". Therapeutic Gastrointestinal Endoscopy. pp. 277–289. doi:10.1007/978-981-13-1184-0_16. ISBN 978-981-13-1184-0.
Bielory L (2002). "Update on ocular allergy treatment". Expert Opinion on Pharmacotherapy. 3 (5): 541–553. doi:10.1517/14656566.3.5.541. PMID 11996633.
Le Blaye I, Donatini B, Hall M, Krupp P (1992). "Acute ketotifen overdosage. A review of present clinical experience". Drug Safety. 7 (5): 387–392. doi:10.2165/00002018-199207050-00007. PMID 1418695. S2CID 25839342.
Jeffreys DB, Volans GN (May 1981). "Ketotifen overdose: surveillance of the toxicity of a new drug". British Medical Journal. 282 (6278): 1755–1756. doi:10.1136/bmj.282.6278.1755. PMC 1505736. PMID 6113023.
"ACE inhibitors". Reactions Weekly (422): 5. 1992. doi:10.2165/00128415-199204220-00009.
Yokoyama H, Hirose M, Uematsu M, Haginoya K, Iinuma K, Kimura S (2012). "Ketotifen overdose. Toxic encephalopathy, epilepsy and mental retardation in an infant: case report". Pediatrics International. 54 (6): 963. doi:10.1111/j.1442-200X.2012.03718.x. PMID 23279031. Archived from the original on 13 April 2024. Retrieved 3 April 2024. In the present case, a 4-month-old boy was administered ketotifen at 5 times the recommended dose, and he showed mental deterioration and growth retardation. The presence of developmental deterioration strongly suggests that overdose of ketotifen induces toxic encephalopathy.
"Ketotifen overdose". Reactions Weekly. 1447: 25. 2013. doi:10.1007/s40278-013-2459-5.
Greenwood C (July 1982). "The pharmacology of ketotifen". Chest. 82 (1 Suppl): 45S – 48S. doi:10.1378/chest.82.1_supplement.45s (inactive 3 December 2024). PMID 6123414.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
Kakiuchi M, Ohashi T, Musoh K, Kawamura K, Morikawa K, Kato H (April 1997). "Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor". Japanese Journal of Pharmacology. 73 (4): 291–298. doi:10.1254/jjp.73.291. PMID 9165365.
Ma C, Li H, Lu S, Li X, Wang S, Wang W (2023). "Tryptase and Exogenous Trypsin: Mechanisms and Ophthalmic Applications". J Inflamm Res. 16: 927–939. doi:10.2147/JIR.S402900. PMC 9987324. PMID 36891173.
Ang DC, Hilligoss J, Stump T (September 2015). "Mast Cell Stabilizer (Ketotifen) in Fibromyalgia: Phase 1 Randomized Controlled Clinical Trial". The Clinical Journal of Pain. 31 (9): 836–842. doi:10.1097/AJP.0000000000000169. PMC 4417653. PMID 25370135.
Li L, Liu R, Peng C, Chen X, Li J (July 2022). "Pharmacogenomics for the efficacy and side effects of antihistamines". Exp Dermatol. 31 (7): 993–1004. doi:10.1111/exd.14602. PMID 35538735.
Muñoz-Cano RM, Casas-Saucedo R, Valero Santiago A, Bobolea I, Ribó P, Mullol J (August 2019). "Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications". J Clin Med. 8 (9): 1338. doi:10.3390/jcm8091338. PMC 6780525. PMID 31470575.
Kahhak L, Roche A, Dubray C, Arnoux C, Benveniste J (May 1996). "Decrease of ciliary beat frequency by platelet activating factor: protective effect of ketotifen". Inflamm Res. 45 (5): 234–8. doi:10.1007/BF02259609. PMID 8737746.
Luna-Gomes T, Bozza PT, Bandeira-Melo C (2013). "Eosinophil recruitment and activation: the role of lipid mediators". Front Pharmacol. 4: 27. doi:10.3389/fphar.2013.00027. PMC 3605515. PMID 23525348.
Martín AP, Urrets-Zavalia J, Berra A, Mariani AL, Gallino N, Gomez Demel E, et al. (January 2003). "The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study". BMC Ophthalmol. 3: 2. doi:10.1186/1471-2415-3-2. PMC 140320. PMID 12515585.
Stone M, Francisco JC, Kumar NN, Barboza J (1 January 2014). "Oral Mast Cell Stabilizers". Encyclopedia of Medical Immunology. pp. 551–555. doi:10.1007/978-1-4614-9194-1_242. ISBN 978-1-4614-9193-4.
Fahmy RH, Badr-Eldin SM (August 2014). "Novel delivery approach for ketotifen fumarate: dissofilms formulation using 3² experimental design: in vitro/in vivo evaluation". Pharm Dev Technol. 19 (5): 521–30. doi:10.3109/10837450.2013.800108. PMID 23713715. S2CID 45012360.
Merk HF (November 2001). "Standard treatment: the role of antihistamines". J Investig Dermatol Symp Proc. 6 (2): 153–6. doi:10.1046/j.0022-202x.2001.00032.x. PMID 11764306.
El-Kommos ME, El-Gizawy SM, Atia NN, Hosny NM (2015). "Analysis for commonly prescribed non-sedating antihistamines". Analytical Chemistry Research. 3: 1–12. doi:10.1016/j.ancr.2014.11.003.
Lieberman P, Hernandez-Trujillo V, Lieberman J, Frew AJ (2008). "Antihistamines". Clinical Immunology. pp. 1317–1329. doi:10.1016/B978-0-323-04404-2.10089-2. ISBN 978-0-323-04404-2. Archived from the original on 24 February 2024. Retrieved 14 February 2024.
Eltze M, Mutschler E, Lambrecht G (1992). "Affinity profiles of pizotifen, ketotifen and other tricyclic antimuscarinics at muscarinic receptor subtypes M1, M2 and M3". European Journal of Pharmacology. 211 (3): 283–293. doi:10.1016/0014-2999(92)90383-F. PMID 1377628.
Sarcina D, Giovannini M, Oranges T, Barni S, Pedaci FA, Liccioli G, et al. (2021). "Case Report and Review of the Literature: Bullous Skin Eruption After the Booster-Dose of Influenza Vaccine in a Pediatric Patient With Polymorphic Maculopapular Cutaneous Mastocytosis". Front Immunol. 12. doi:10.3389/fimmu.2021.688364. PMC 8322976. PMID 34335590.
Bittner L, Teixidó E, Keddi I, Escher BI, Klüver N (May 2019). "pH-Dependent Uptake and Sublethal Effects of Antihistamines in Zebrafish (Danio rerio) Embryos". Environmental Toxicology and Chemistry. 38 (5): 1012–1022. Bibcode:2019EnvTC..38.1012B. doi:10.1002/etc.4395. PMID 30779379. S2CID 73482611.
Pinke KH, Zorzella-Pezavento SF, de Campos Fraga-Silva TF, Mimura LA, de Oliveira LR, Ishikawa LL, et al. (January 2020). "Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?". Neurotherapeutics. 17 (1): 218–234. doi:10.1007/s13311-019-00775-8. PMC 7007452. PMID 31463682.
Janeczko P, Norris MR, Bielory L (October 2021). "Assessment of receptor affinities of ophthalmic and systemic agents in dry eye disease". Current Opinion in Allergy and Clinical Immunology. 21 (5): 480–485. doi:10.1097/ACI.0000000000000773. PMID 34387278. S2CID 236998913.
Triantafillou V, Maina IW, Patel NN, Tong CC, Papagiannopoulos P, Kohanski MA, et al. (February 2020). "In vitro safety of ketotifen as a topical nasal rinse". International Forum of Allergy & Rhinology. 10 (2): 265–270. doi:10.1002/alr.22461. PMID 32086998. S2CID 211246051.
Slater JW, Zechnich AD, Haxby DG (January 1999). "Second-generation antihistamines: a comparative review". Drugs. 57 (1): 31–47. doi:10.2165/00003495-199957010-00004. PMID 9951950. S2CID 24659435.
Sagara A, Nagahama A, Aki H, Yoshimura H, Hiraide M, Shimizu T, et al. (October 2023). "Potential risk of driving performance under combined conditions of taking second-generation antihistamines and attending calls using a hands-free function". Traffic Injury Prevention. 25 (1): 36–40. doi:10.1080/15389588.2023.2265002. PMID 37815801. S2CID 263801715.
Aelony Y (September 1998). "First-generation vs second-generation antihistamines". Archives of Internal Medicine. 158 (17): 1949–1950. doi:10.1001/archinte.158.17.1949 (inactive 24 November 2024). PMID 9759694.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Chiriac AM, Bousquet J, Demoly P (2017). "Principles of Allergy Diagnosis". Middleton's Allergy Essentials. pp. 117–131. doi:10.1016/B978-0-323-37579-5.00005-2. ISBN 978-0-323-37579-5. Archived from the original on 24 February 2024. Retrieved 14 February 2024.
MacDonald G (1982). "An Overview of Ketotifen". Chest. 82 (1 Suppl): 30s – 32s. doi:10.1378/chest.82.1.30S. PMID 6806019. Archived from the original on 13 April 2024. Retrieved 13 April 2024.
Finn DF, Walsh JJ (September 2013). "Twenty-first century mast cell stabilizers". Br J Pharmacol. 170 (1): 23–37. doi:10.1111/bph.12138. PMC 3764846. PMID 23441583.
Zhang L, Song J, Hou X (April 2016). "Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside". Journal of Neurogastroenterology and Motility. 22 (2): 181–192. doi:10.5056/jnm15137. PMC 4819856. PMID 26755686.
Aberg AK, Arulnesan N, Bolger GT, Ciofalo VB, Pucaj K, Walle K, et al. (April 2022). "Ketotifen is a Prodrug. Norketotifen is the active metabolite". Drug Development Research. 83 (2): 362–367. doi:10.1002/ddr.21865. PMID 34410005. S2CID 237216445.
Habibi Asl B, Vaez H, Imankhah T, Hamidi S (2014). "Impact of caffeine on weight changes due to ketotifen administration". Advanced Pharmaceutical Bulletin. 4 (1): 83–89. doi:10.5681/apb.2014.013. PMC 3885374. PMID 24409414.
Asnaashari S, Delazar A, Habibi B, Vasfi R, Nahar L, Hamedeyazdan S, et al. (December 2010). "Essential oil from Citrus aurantifolia prevents ketotifen-induced weight-gain in mice". Phytotherapy Research. 24 (12): 1893–1897. doi:10.1002/ptr.3227. PMID 20623616. S2CID 8888404. Archived from the original on 28 January 2024. Retrieved 10 January 2024.
Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, et al. (September 2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome" (PDF). Gut. 59 (9): 1213–1221. doi:10.1136/gut.2010.213108. PMID 20650926. S2CID 18889707. Archived (PDF) from the original on 11 June 2021. Retrieved 24 September 2019.

drugbank.com

go.drugbank.com

"Ketotifen". Drugbank. 12 April 2024. Archived from the original on 6 August 2019. Retrieved 16 November 2023.

drugs.com

"Ketotifen ophthalmic Uses, Side Effects & Warnings". Archived from the original on 16 November 2023. Retrieved 16 November 2023.
"Ketotifen Monograph for Professionals". Archived from the original on 11 June 2021. Retrieved 16 November 2023.
"Ketotifen (Oral) Advanced Patient Information". Archived from the original on 2 December 2023. Retrieved 11 March 2024.
"Ketotifen (Oral) Advanced Patient Information". Archived from the original on 2 December 2023. Retrieved 11 March 2024.
"Ketotifen International". Drugs.com. Archived from the original on 11 April 2021. Retrieved 4 September 2020.
"Ketotifen (Ingredient)". Archived from the original on 2 April 2024. Retrieved 2 April 2024.

europa.eu

ema.europa.eu

"List of nationally authorised medicinal products" (PDF). European Medicines Agency. 14 June 2018. Archived (PDF) from the original on 13 April 2024. Retrieved 13 April 2024.

fda.gov

accessdata.fda.gov

"Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen), for ophthalmic use" (PDF). 2022. Archived (PDF) from the original on 8 March 2024. Retrieved 13 April 2024.
"Center for drug evaluation and research. Application no. 21-066" (PDF). Archived (PDF) from the original on 14 February 2024. Retrieved 14 February 2024.
"Drug Approval Package: Zaditor (Ketotifen Fumarate) NDA# 21-066". accessdata.fda.gov. 20 November 2001. Archived from the original on 8 March 2024. Retrieved 10 March 2024.
"Drug Approval Package: Acuvue Theravision with ketotifen". accessdata.fda.gov. 19 September 2022. Archived from the original on 10 March 2024. Retrieved 10 March 2024.

hal.science

Asnaashari S, Delazar A, Habibi B, Vasfi R, Nahar L, Hamedeyazdan S, et al. (December 2010). "Essential oil from Citrus aurantifolia prevents ketotifen-induced weight-gain in mice". Phytotherapy Research. 24 (12): 1893–1897. doi:10.1002/ptr.3227. PMID 20623616. S2CID 8888404. Archived from the original on 28 January 2024. Retrieved 10 January 2024.

harvard.edu

ui.adsabs.harvard.edu

Sastre E, Caracuel L, Xavier FE, Balfagón G, Blanco-Rivero J (2013). "Opposite effect of mast cell stabilizers ketotifen and tranilast on the vasoconstrictor response to electrical field stimulation in rat mesenteric artery". PLOS ONE. 8 (8): e73232. Bibcode:2013PLoSO...873232S. doi:10.1371/journal.pone.0073232. PMC 3748149. PMID 23977380.
Bittner L, Teixidó E, Keddi I, Escher BI, Klüver N (May 2019). "pH-Dependent Uptake and Sublethal Effects of Antihistamines in Zebrafish (Danio rerio) Embryos". Environmental Toxicology and Chemistry. 38 (5): 1012–1022. Bibcode:2019EnvTC..38.1012B. doi:10.1002/etc.4395. PMID 30779379. S2CID 73482611.

hres.ca

pdf.hres.ca

"Tablets, 1 mg ketotifen (as ketotifen hydrogen fumarate), Oral (product monograph)" (PDF). Archived (PDF) from the original on 21 February 2024. Retrieved 11 March 2024.

hsa.gov.sg

"Ketotifen 2mg Tablets, 1mg/5mL Oral Solution (product monograph)" (PDF). Archived (PDF) from the original on 18 July 2022. Retrieved 11 March 2024.

ichgcp.net

"Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness". 25 January 2023. Archived from the original on 20 April 2024. Retrieved 13 April 2024.
"Norketotifen in Influenza -Like Illness - Clinical Trials Registry - ICH GCP". Archived from the original on 13 April 2024. Retrieved 13 April 2024.

jjvision.com

"Johnson & Johnson Vision Care Receives FDA Approval for Acuvue Theravision with Ketotifen – World's First and Only Drug-Eluting Contact Lens". Johnson and Johnson Vision (Press release). 2 March 2022. Archived from the original on 11 March 2024. Retrieved 10 March 2024.

medicines.org.uk

"Zaditen Summary of Product Characteristics (SmPC)". emc. 13 October 2020. Archived from the original on 10 March 2024. Retrieved 10 March 2024.

merckmanuals.com

"Angle-Closure Glaucoma - Angle-Closure Glaucoma". Archived from the original on 17 May 2024. Retrieved 15 October 2024.

mims.co.uk

"Zaditen - MIMS online". www.mims.co.uk. Archived from the original on 25 October 2020. Retrieved 2 August 2017.

msn.com

Tata (28 March 2024). "What To Know About Ketotifen (popular Brands: Ketasma And Asthafen)". MSN. Archived from the original on 13 April 2024. Retrieved 2 April 2024.

ncats.io

drugs.ncats.io

"Ketotifen Fumarate". Inxight Drugs. Bethesda MD, US: National Center for Advancing Translational Sciences (NCATS). 12 April 2024. Archived from the original on 13 April 2024. Retrieved 13 April 2024.

nih.gov

pubmed.ncbi.nlm.nih.gov

Grant SM, Goa KL, Fitton A, Sorkin EM (September 1990). "Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders". Drugs. 40 (3): 412–448. doi:10.2165/00003495-199040030-00006. PMID 2226222. S2CID 242916740.
Ono J, Toshida H (July 2022). "Use of Ketotifen Fumarate-Eluting Daily Disposable Soft Contact Lens in Management of Ocular Allergy: Literature Review and Report of Two Cases". Cureus. 14 (7): e27093. doi:10.7759/cureus.27093. PMC 9391663. PMID 36000122.
García-Martín E, Canto G, Agúndez JA (November 2013). "Metabolic considerations of drugs in the treatment of allergic diseases". Expert Opin Drug Metab Toxicol. 9 (11): 1437–52. doi:10.1517/17425255.2013.823400. PMID 23902458. S2CID 30634949.
Dou XY, Zhang W (2023). "Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis". Int J Ophthalmol. 16 (2): 286–292. doi:10.18240/ijo.2023.02.17. PMC 9922628. PMID 36816214.
Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. (October 2009). "EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria". Allergy. 64 (10): 1427–1443. doi:10.1111/j.1398-9995.2009.02178.x. PMID 19772513. S2CID 14587946.
Sokol KC, Amar NK, Starkey J, Grant JA (December 2013). "Ketotifen in the management of chronic urticaria: resurrection of an old drug". Annals of Allergy, Asthma & Immunology. 111 (6): 433–436. doi:10.1016/j.anai.2013.10.003. PMC 4309375. PMID 24267353.
Zuberbier T (January 2012). "A Summary of the New International EAACI/GA(2)LEN/EDF/WAO Guidelines in Urticaria". The World Allergy Organization Journal. 5 (Suppl 1): S1 – S5. doi:10.1186/1939-4551-5-S1-S1. PMC 3488932. PMID 23282889.
Frieri M (June 2018). "Mast Cell Activation Syndrome". Clin Rev Allergy Immunol. 54 (3): 353–365. doi:10.1007/s12016-015-8487-6. PMID 25944644. S2CID 5723622.
Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, et al. (2018). "The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets". Front Immunol. 9: 1873. doi:10.3389/fimmu.2018.01873. PMC 6099187. PMID 30150993.
Simons FE, Simons KJ (December 2011). "Histamine and H1-antihistamines: celebrating a century of progress". J Allergy Clin Immunol. 128 (6): 1139–1150.e4. doi:10.1016/j.jaci.2011.09.005. PMID 22035879.
Linton S, Hossenbaccus L, Ellis AK (October 2023). "Evidence-based use of antihistamines for treatment of allergic conditions". Ann Allergy Asthma Immunol. 131 (4): 412–420. doi:10.1016/j.anai.2023.07.019. PMID 37517656.
Ormerod AD (November 1994). "Urticaria. Recognition, causes and treatment". Drugs. 48 (5): 717–30. doi:10.2165/00003495-199448050-00006. PMID 7530629.
Sastre E, Caracuel L, Xavier FE, Balfagón G, Blanco-Rivero J (2013). "Opposite effect of mast cell stabilizers ketotifen and tranilast on the vasoconstrictor response to electrical field stimulation in rat mesenteric artery". PLOS ONE. 8 (8): e73232. Bibcode:2013PLoSO...873232S. doi:10.1371/journal.pone.0073232. PMC 3748149. PMID 23977380.
Suzuki Y, Inoue T, Ra C (14 February 2012). "Calcium Signaling in Mast Cells: Focusing on L-Type Calcium Channels". Calcium Signaling. Advances in Experimental Medicine and Biology. Vol. 740. pp. 955–977. doi:10.1007/978-94-007-2888-2_44. ISBN 978-94-007-2888-2. PMID 22453979.
Holowka D, Wilkes M, Stefan C, Baird B (April 2016). "Roles for Ca2+ mobilization and its regulation in mast cell functions: recent progress". Biochem Soc Trans. 44 (2): 505–9. doi:10.1042/BST20150273. PMC 5293407. PMID 27068962.
El-Alali EA, Abukhiran IM, Alhmoud TZ (July 2021). "Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review". BMC Gastroenterology. 21 (1): 279. doi:10.1186/s12876-021-01854-x. PMC 8265096. PMID 34238222.
MacDonald G (1982). "An Overview of Ketotifen". Chest. 82 (1 Suppl): 30s – 32s. doi:10.1378/chest.82.1.30S. PMID 6806019. Archived from the original on 17 July 2024. Retrieved 17 July 2024.
Schwarzer G, Bassler D, Mitra A, Ducharme FM, Forster J (2004). "Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children". Cochrane Database Syst Rev. 2004 (1): CD001384. doi:10.1002/14651858.CD001384.pub2. PMC 8406918. PMID 14973969.
Grahnén A, Lönnebo A, Beck O, Eckernäs SA, Dahlström B, Lindström B (May 1992). "Pharmacokinetics of ketotifen after oral administration to healthy male subjects". Biopharmaceutics & Drug Disposition. 13 (4): 255–262. doi:10.1002/bdd.2510130404. PMID 1600111. S2CID 72293850.
Zhu TH, Zou G, Ding SJ, Li TT, Zhu LB, Wang JZ, et al. (2019). "Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis". J Pain Res. 12: 1359–1369. doi:10.2147/JPR.S195909. PMC 6500880. PMID 31118754. Ketotifen has a stronger effect on stabilizing MCs than sodium cromoglycate. This drug has antihistamine activity and is also a functional leukotriene antagonist
Sasaki F, Yokomizo T (August 2019). "The leukotriene receptors as therapeutic targets of inflammatory diseases". Int Immunol. 31 (9): 607–615. doi:10.1093/intimm/dxz044. PMID 31135881.
Mostafa GA, Bakheit A, AlMasoud N, AlRabiah H (April 2021). "Charge Transfer Complexes of Ketotifen with 2,3-Dichloro-5,6-dicyano-p-benzoquinone and 7,7,8,8-Tetracyanoquodimethane: Spectroscopic Characterization Studies". Molecules. 26 (7): 2039. doi:10.3390/molecules26072039. PMC 8038309. PMID 33918481.
Castillo JG, Gamboa PM, García BE, Oehling A (1990). "Effect of ketotifen on phosphodiesterase activity from asthmatic individuals". Allergologia et Immunopathologia. 18 (4): 197–201. PMID 1702263.
Omori K, Kotera J (February 2007). "Overview of PDEs and their regulation". Circ Res. 100 (3): 309–27. doi:10.1161/01.RES.0000256354.95791.f1. PMID 17307970.
Yokoyama H, Iinuma K (18 November 2012) [May 1996]. "Histamine and Seizures". CNS Drugs. 5 (5): 321–330. doi:10.2165/00023210-199605050-00002. PMID 26071045.
Jue TL, Storm AC, Naveed M, Fishman DS, Qumseya BJ, McRee AJ, et al. (2021). "ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction". Gastrointestinal Endoscopy. 93 (2): 309–322.e4. doi:10.1016/j.gie.2020.07.063. PMID 33168194.
Bielory L (2002). "Update on ocular allergy treatment". Expert Opinion on Pharmacotherapy. 3 (5): 541–553. doi:10.1517/14656566.3.5.541. PMID 11996633.
Ketotifen. National Institute of Child Health and Human Development. 2006. PMID 30000587. NCBI NBK501527. Archived from the original on 3 October 2023. Retrieved 22 November 2023.
Le Blaye I, Donatini B, Hall M, Krupp P (1992). "Acute ketotifen overdosage. A review of present clinical experience". Drug Safety. 7 (5): 387–392. doi:10.2165/00002018-199207050-00007. PMID 1418695. S2CID 25839342.
Jeffreys DB, Volans GN (May 1981). "Ketotifen overdose: surveillance of the toxicity of a new drug". British Medical Journal. 282 (6278): 1755–1756. doi:10.1136/bmj.282.6278.1755. PMC 1505736. PMID 6113023.
Yokoyama H, Hirose M, Uematsu M, Haginoya K, Iinuma K, Kimura S (2012). "Ketotifen overdose. Toxic encephalopathy, epilepsy and mental retardation in an infant: case report". Pediatrics International. 54 (6): 963. doi:10.1111/j.1442-200X.2012.03718.x. PMID 23279031. Archived from the original on 13 April 2024. Retrieved 3 April 2024. In the present case, a 4-month-old boy was administered ketotifen at 5 times the recommended dose, and he showed mental deterioration and growth retardation. The presence of developmental deterioration strongly suggests that overdose of ketotifen induces toxic encephalopathy.
Greenwood C (July 1982). "The pharmacology of ketotifen". Chest. 82 (1 Suppl): 45S – 48S. doi:10.1378/chest.82.1_supplement.45s (inactive 3 December 2024). PMID 6123414.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
Rogóz Z, Skuza G, Sowińska H (1981). "Central action of ketotifen". Polish Journal of Pharmacology and Pharmacy. 33 (5): 503–515. PMID 7335554.
Kakiuchi M, Ohashi T, Musoh K, Kawamura K, Morikawa K, Kato H (April 1997). "Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor". Japanese Journal of Pharmacology. 73 (4): 291–298. doi:10.1254/jjp.73.291. PMID 9165365.
Ma C, Li H, Lu S, Li X, Wang S, Wang W (2023). "Tryptase and Exogenous Trypsin: Mechanisms and Ophthalmic Applications". J Inflamm Res. 16: 927–939. doi:10.2147/JIR.S402900. PMC 9987324. PMID 36891173.
Ang DC, Hilligoss J, Stump T (September 2015). "Mast Cell Stabilizer (Ketotifen) in Fibromyalgia: Phase 1 Randomized Controlled Clinical Trial". The Clinical Journal of Pain. 31 (9): 836–842. doi:10.1097/AJP.0000000000000169. PMC 4417653. PMID 25370135.
Li L, Liu R, Peng C, Chen X, Li J (July 2022). "Pharmacogenomics for the efficacy and side effects of antihistamines". Exp Dermatol. 31 (7): 993–1004. doi:10.1111/exd.14602. PMID 35538735.
Muñoz-Cano RM, Casas-Saucedo R, Valero Santiago A, Bobolea I, Ribó P, Mullol J (August 2019). "Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications". J Clin Med. 8 (9): 1338. doi:10.3390/jcm8091338. PMC 6780525. PMID 31470575.
Kahhak L, Roche A, Dubray C, Arnoux C, Benveniste J (May 1996). "Decrease of ciliary beat frequency by platelet activating factor: protective effect of ketotifen". Inflamm Res. 45 (5): 234–8. doi:10.1007/BF02259609. PMID 8737746.
Luna-Gomes T, Bozza PT, Bandeira-Melo C (2013). "Eosinophil recruitment and activation: the role of lipid mediators". Front Pharmacol. 4: 27. doi:10.3389/fphar.2013.00027. PMC 3605515. PMID 23525348.
Martín AP, Urrets-Zavalia J, Berra A, Mariani AL, Gallino N, Gomez Demel E, et al. (January 2003). "The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study". BMC Ophthalmol. 3: 2. doi:10.1186/1471-2415-3-2. PMC 140320. PMID 12515585.
Fahmy RH, Badr-Eldin SM (August 2014). "Novel delivery approach for ketotifen fumarate: dissofilms formulation using 3² experimental design: in vitro/in vivo evaluation". Pharm Dev Technol. 19 (5): 521–30. doi:10.3109/10837450.2013.800108. PMID 23713715. S2CID 45012360.
Merk HF (November 2001). "Standard treatment: the role of antihistamines". J Investig Dermatol Symp Proc. 6 (2): 153–6. doi:10.1046/j.0022-202x.2001.00032.x. PMID 11764306.
Jáuregui I, Mullol J, Bartra J, del Cuvillo A, Dávila I, Montoro J, et al. (2006). "H1 antihistamines: psychomotor performance and driving". J Investig Allergol Clin Immunol. 16 (Suppl 1): 37–44. PMID 17357376.
Eltze M, Mutschler E, Lambrecht G (1992). "Affinity profiles of pizotifen, ketotifen and other tricyclic antimuscarinics at muscarinic receptor subtypes M1, M2 and M3". European Journal of Pharmacology. 211 (3): 283–293. doi:10.1016/0014-2999(92)90383-F. PMID 1377628.
Sarcina D, Giovannini M, Oranges T, Barni S, Pedaci FA, Liccioli G, et al. (2021). "Case Report and Review of the Literature: Bullous Skin Eruption After the Booster-Dose of Influenza Vaccine in a Pediatric Patient With Polymorphic Maculopapular Cutaneous Mastocytosis". Front Immunol. 12. doi:10.3389/fimmu.2021.688364. PMC 8322976. PMID 34335590.
Bittner L, Teixidó E, Keddi I, Escher BI, Klüver N (May 2019). "pH-Dependent Uptake and Sublethal Effects of Antihistamines in Zebrafish (Danio rerio) Embryos". Environmental Toxicology and Chemistry. 38 (5): 1012–1022. Bibcode:2019EnvTC..38.1012B. doi:10.1002/etc.4395. PMID 30779379. S2CID 73482611.
Pinke KH, Zorzella-Pezavento SF, de Campos Fraga-Silva TF, Mimura LA, de Oliveira LR, Ishikawa LL, et al. (January 2020). "Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?". Neurotherapeutics. 17 (1): 218–234. doi:10.1007/s13311-019-00775-8. PMC 7007452. PMID 31463682.
Janeczko P, Norris MR, Bielory L (October 2021). "Assessment of receptor affinities of ophthalmic and systemic agents in dry eye disease". Current Opinion in Allergy and Clinical Immunology. 21 (5): 480–485. doi:10.1097/ACI.0000000000000773. PMID 34387278. S2CID 236998913.
Triantafillou V, Maina IW, Patel NN, Tong CC, Papagiannopoulos P, Kohanski MA, et al. (February 2020). "In vitro safety of ketotifen as a topical nasal rinse". International Forum of Allergy & Rhinology. 10 (2): 265–270. doi:10.1002/alr.22461. PMID 32086998. S2CID 211246051.
Slater JW, Zechnich AD, Haxby DG (January 1999). "Second-generation antihistamines: a comparative review". Drugs. 57 (1): 31–47. doi:10.2165/00003495-199957010-00004. PMID 9951950. S2CID 24659435.
Sagara A, Nagahama A, Aki H, Yoshimura H, Hiraide M, Shimizu T, et al. (October 2023). "Potential risk of driving performance under combined conditions of taking second-generation antihistamines and attending calls using a hands-free function". Traffic Injury Prevention. 25 (1): 36–40. doi:10.1080/15389588.2023.2265002. PMID 37815801. S2CID 263801715.
Aelony Y (September 1998). "First-generation vs second-generation antihistamines". Archives of Internal Medicine. 158 (17): 1949–1950. doi:10.1001/archinte.158.17.1949 (inactive 24 November 2024). PMID 9759694.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
MacDonald G (1982). "An Overview of Ketotifen". Chest. 82 (1 Suppl): 30s – 32s. doi:10.1378/chest.82.1.30S. PMID 6806019. Archived from the original on 13 April 2024. Retrieved 13 April 2024.
Finn DF, Walsh JJ (September 2013). "Twenty-first century mast cell stabilizers". Br J Pharmacol. 170 (1): 23–37. doi:10.1111/bph.12138. PMC 3764846. PMID 23441583.
Zhang L, Song J, Hou X (April 2016). "Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside". Journal of Neurogastroenterology and Motility. 22 (2): 181–192. doi:10.5056/jnm15137. PMC 4819856. PMID 26755686.
Aberg AK, Arulnesan N, Bolger GT, Ciofalo VB, Pucaj K, Walle K, et al. (April 2022). "Ketotifen is a Prodrug. Norketotifen is the active metabolite". Drug Development Research. 83 (2): 362–367. doi:10.1002/ddr.21865. PMID 34410005. S2CID 237216445.
Habibi Asl B, Vaez H, Imankhah T, Hamidi S (2014). "Impact of caffeine on weight changes due to ketotifen administration". Advanced Pharmaceutical Bulletin. 4 (1): 83–89. doi:10.5681/apb.2014.013. PMC 3885374. PMID 24409414.
Asnaashari S, Delazar A, Habibi B, Vasfi R, Nahar L, Hamedeyazdan S, et al. (December 2010). "Essential oil from Citrus aurantifolia prevents ketotifen-induced weight-gain in mice". Phytotherapy Research. 24 (12): 1893–1897. doi:10.1002/ptr.3227. PMID 20623616. S2CID 8888404. Archived from the original on 28 January 2024. Retrieved 10 January 2024.
Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, et al. (September 2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome" (PDF). Gut. 59 (9): 1213–1221. doi:10.1136/gut.2010.213108. PMID 20650926. S2CID 18889707. Archived (PDF) from the original on 11 June 2021. Retrieved 24 September 2019.

ncbi.nlm.nih.gov

Ono J, Toshida H (July 2022). "Use of Ketotifen Fumarate-Eluting Daily Disposable Soft Contact Lens in Management of Ocular Allergy: Literature Review and Report of Two Cases". Cureus. 14 (7): e27093. doi:10.7759/cureus.27093. PMC 9391663. PMID 36000122.
Dou XY, Zhang W (2023). "Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis". Int J Ophthalmol. 16 (2): 286–292. doi:10.18240/ijo.2023.02.17. PMC 9922628. PMID 36816214.
Sokol KC, Amar NK, Starkey J, Grant JA (December 2013). "Ketotifen in the management of chronic urticaria: resurrection of an old drug". Annals of Allergy, Asthma & Immunology. 111 (6): 433–436. doi:10.1016/j.anai.2013.10.003. PMC 4309375. PMID 24267353.
Zuberbier T (January 2012). "A Summary of the New International EAACI/GA(2)LEN/EDF/WAO Guidelines in Urticaria". The World Allergy Organization Journal. 5 (Suppl 1): S1 – S5. doi:10.1186/1939-4551-5-S1-S1. PMC 3488932. PMID 23282889.
Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, et al. (2018). "The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets". Front Immunol. 9: 1873. doi:10.3389/fimmu.2018.01873. PMC 6099187. PMID 30150993.
Sastre E, Caracuel L, Xavier FE, Balfagón G, Blanco-Rivero J (2013). "Opposite effect of mast cell stabilizers ketotifen and tranilast on the vasoconstrictor response to electrical field stimulation in rat mesenteric artery". PLOS ONE. 8 (8): e73232. Bibcode:2013PLoSO...873232S. doi:10.1371/journal.pone.0073232. PMC 3748149. PMID 23977380.
Holowka D, Wilkes M, Stefan C, Baird B (April 2016). "Roles for Ca2+ mobilization and its regulation in mast cell functions: recent progress". Biochem Soc Trans. 44 (2): 505–9. doi:10.1042/BST20150273. PMC 5293407. PMID 27068962.
El-Alali EA, Abukhiran IM, Alhmoud TZ (July 2021). "Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review". BMC Gastroenterology. 21 (1): 279. doi:10.1186/s12876-021-01854-x. PMC 8265096. PMID 34238222.
Schwarzer G, Bassler D, Mitra A, Ducharme FM, Forster J (2004). "Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children". Cochrane Database Syst Rev. 2004 (1): CD001384. doi:10.1002/14651858.CD001384.pub2. PMC 8406918. PMID 14973969.
Zhu TH, Zou G, Ding SJ, Li TT, Zhu LB, Wang JZ, et al. (2019). "Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis". J Pain Res. 12: 1359–1369. doi:10.2147/JPR.S195909. PMC 6500880. PMID 31118754. Ketotifen has a stronger effect on stabilizing MCs than sodium cromoglycate. This drug has antihistamine activity and is also a functional leukotriene antagonist
Mostafa GA, Bakheit A, AlMasoud N, AlRabiah H (April 2021). "Charge Transfer Complexes of Ketotifen with 2,3-Dichloro-5,6-dicyano-p-benzoquinone and 7,7,8,8-Tetracyanoquodimethane: Spectroscopic Characterization Studies". Molecules. 26 (7): 2039. doi:10.3390/molecules26072039. PMC 8038309. PMID 33918481.
Ketotifen. National Institute of Child Health and Human Development. 2006. PMID 30000587. NCBI NBK501527. Archived from the original on 3 October 2023. Retrieved 22 November 2023.
Jeffreys DB, Volans GN (May 1981). "Ketotifen overdose: surveillance of the toxicity of a new drug". British Medical Journal. 282 (6278): 1755–1756. doi:10.1136/bmj.282.6278.1755. PMC 1505736. PMID 6113023.
Ma C, Li H, Lu S, Li X, Wang S, Wang W (2023). "Tryptase and Exogenous Trypsin: Mechanisms and Ophthalmic Applications". J Inflamm Res. 16: 927–939. doi:10.2147/JIR.S402900. PMC 9987324. PMID 36891173.
Ang DC, Hilligoss J, Stump T (September 2015). "Mast Cell Stabilizer (Ketotifen) in Fibromyalgia: Phase 1 Randomized Controlled Clinical Trial". The Clinical Journal of Pain. 31 (9): 836–842. doi:10.1097/AJP.0000000000000169. PMC 4417653. PMID 25370135.
Muñoz-Cano RM, Casas-Saucedo R, Valero Santiago A, Bobolea I, Ribó P, Mullol J (August 2019). "Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications". J Clin Med. 8 (9): 1338. doi:10.3390/jcm8091338. PMC 6780525. PMID 31470575.
Luna-Gomes T, Bozza PT, Bandeira-Melo C (2013). "Eosinophil recruitment and activation: the role of lipid mediators". Front Pharmacol. 4: 27. doi:10.3389/fphar.2013.00027. PMC 3605515. PMID 23525348.
Martín AP, Urrets-Zavalia J, Berra A, Mariani AL, Gallino N, Gomez Demel E, et al. (January 2003). "The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study". BMC Ophthalmol. 3: 2. doi:10.1186/1471-2415-3-2. PMC 140320. PMID 12515585.
Sarcina D, Giovannini M, Oranges T, Barni S, Pedaci FA, Liccioli G, et al. (2021). "Case Report and Review of the Literature: Bullous Skin Eruption After the Booster-Dose of Influenza Vaccine in a Pediatric Patient With Polymorphic Maculopapular Cutaneous Mastocytosis". Front Immunol. 12. doi:10.3389/fimmu.2021.688364. PMC 8322976. PMID 34335590.
Pinke KH, Zorzella-Pezavento SF, de Campos Fraga-Silva TF, Mimura LA, de Oliveira LR, Ishikawa LL, et al. (January 2020). "Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?". Neurotherapeutics. 17 (1): 218–234. doi:10.1007/s13311-019-00775-8. PMC 7007452. PMID 31463682.
Finn DF, Walsh JJ (September 2013). "Twenty-first century mast cell stabilizers". Br J Pharmacol. 170 (1): 23–37. doi:10.1111/bph.12138. PMC 3764846. PMID 23441583.
Zhang L, Song J, Hou X (April 2016). "Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside". Journal of Neurogastroenterology and Motility. 22 (2): 181–192. doi:10.5056/jnm15137. PMC 4819856. PMID 26755686.
Habibi Asl B, Vaez H, Imankhah T, Hamidi S (2014). "Impact of caffeine on weight changes due to ketotifen administration". Advanced Pharmaceutical Bulletin. 4 (1): 83–89. doi:10.5681/apb.2014.013. PMC 3885374. PMID 24409414.

dailymed.nlm.nih.gov

"Zaditor- ketotifen fumarate solution". DailyMed. 13 February 2020. Archived from the original on 11 June 2021. Retrieved 4 September 2020.
"Acuvue Theravision with ketotifen". DailyMed. 11 March 2022. Archived from the original on 3 December 2023.
"DailyMed - ZADITOR- ketotifen fumarate solution". National Institutes of Health. 15 December 2023. Archived from the original on 11 June 2021. Retrieved 5 September 2020.

pediatriconcall.com

"Ketotifen - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose; Drug Index; Pediatric Oncall". Pediatric Oncall. Archived from the original on 16 November 2023. Retrieved 16 November 2023.

proquest.com

Yokoyama H, Hirose M, Uematsu M, Haginoya K, Iinuma K, Kimura S (2012). "Ketotifen overdose. Toxic encephalopathy, epilepsy and mental retardation in an infant: case report". Pediatrics International. 54 (6): 963. doi:10.1111/j.1442-200X.2012.03718.x. PMID 23279031. Archived from the original on 13 April 2024. Retrieved 3 April 2024. In the present case, a 4-month-old boy was administered ketotifen at 5 times the recommended dose, and he showed mental deterioration and growth retardation. The presence of developmental deterioration strongly suggests that overdose of ketotifen induces toxic encephalopathy.

rxlist.com

"Ketotifen Ophthalmic: Generic, Uses, Side Effects, Dosages, Interactions, Warnings". Archived from the original on 24 February 2024. Retrieved 1 December 2023.

semanticscholar.org

api.semanticscholar.org

Grant SM, Goa KL, Fitton A, Sorkin EM (September 1990). "Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders". Drugs. 40 (3): 412–448. doi:10.2165/00003495-199040030-00006. PMID 2226222. S2CID 242916740.
García-Martín E, Canto G, Agúndez JA (November 2013). "Metabolic considerations of drugs in the treatment of allergic diseases". Expert Opin Drug Metab Toxicol. 9 (11): 1437–52. doi:10.1517/17425255.2013.823400. PMID 23902458. S2CID 30634949.
Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. (October 2009). "EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria". Allergy. 64 (10): 1427–1443. doi:10.1111/j.1398-9995.2009.02178.x. PMID 19772513. S2CID 14587946.
Frieri M (June 2018). "Mast Cell Activation Syndrome". Clin Rev Allergy Immunol. 54 (3): 353–365. doi:10.1007/s12016-015-8487-6. PMID 25944644. S2CID 5723622.
Grahnén A, Lönnebo A, Beck O, Eckernäs SA, Dahlström B, Lindström B (May 1992). "Pharmacokinetics of ketotifen after oral administration to healthy male subjects". Biopharmaceutics & Drug Disposition. 13 (4): 255–262. doi:10.1002/bdd.2510130404. PMID 1600111. S2CID 72293850.
Le Blaye I, Donatini B, Hall M, Krupp P (1992). "Acute ketotifen overdosage. A review of present clinical experience". Drug Safety. 7 (5): 387–392. doi:10.2165/00002018-199207050-00007. PMID 1418695. S2CID 25839342.
Fahmy RH, Badr-Eldin SM (August 2014). "Novel delivery approach for ketotifen fumarate: dissofilms formulation using 3² experimental design: in vitro/in vivo evaluation". Pharm Dev Technol. 19 (5): 521–30. doi:10.3109/10837450.2013.800108. PMID 23713715. S2CID 45012360.
Bittner L, Teixidó E, Keddi I, Escher BI, Klüver N (May 2019). "pH-Dependent Uptake and Sublethal Effects of Antihistamines in Zebrafish (Danio rerio) Embryos". Environmental Toxicology and Chemistry. 38 (5): 1012–1022. Bibcode:2019EnvTC..38.1012B. doi:10.1002/etc.4395. PMID 30779379. S2CID 73482611.
Janeczko P, Norris MR, Bielory L (October 2021). "Assessment of receptor affinities of ophthalmic and systemic agents in dry eye disease". Current Opinion in Allergy and Clinical Immunology. 21 (5): 480–485. doi:10.1097/ACI.0000000000000773. PMID 34387278. S2CID 236998913.
Triantafillou V, Maina IW, Patel NN, Tong CC, Papagiannopoulos P, Kohanski MA, et al. (February 2020). "In vitro safety of ketotifen as a topical nasal rinse". International Forum of Allergy & Rhinology. 10 (2): 265–270. doi:10.1002/alr.22461. PMID 32086998. S2CID 211246051.
Slater JW, Zechnich AD, Haxby DG (January 1999). "Second-generation antihistamines: a comparative review". Drugs. 57 (1): 31–47. doi:10.2165/00003495-199957010-00004. PMID 9951950. S2CID 24659435.
Sagara A, Nagahama A, Aki H, Yoshimura H, Hiraide M, Shimizu T, et al. (October 2023). "Potential risk of driving performance under combined conditions of taking second-generation antihistamines and attending calls using a hands-free function". Traffic Injury Prevention. 25 (1): 36–40. doi:10.1080/15389588.2023.2265002. PMID 37815801. S2CID 263801715.
Aberg AK, Arulnesan N, Bolger GT, Ciofalo VB, Pucaj K, Walle K, et al. (April 2022). "Ketotifen is a Prodrug. Norketotifen is the active metabolite". Drug Development Research. 83 (2): 362–367. doi:10.1002/ddr.21865. PMID 34410005. S2CID 237216445.
Asnaashari S, Delazar A, Habibi B, Vasfi R, Nahar L, Hamedeyazdan S, et al. (December 2010). "Essential oil from Citrus aurantifolia prevents ketotifen-induced weight-gain in mice". Phytotherapy Research. 24 (12): 1893–1897. doi:10.1002/ptr.3227. PMID 20623616. S2CID 8888404. Archived from the original on 28 January 2024. Retrieved 10 January 2024.
Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, et al. (September 2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome" (PDF). Gut. 59 (9): 1213–1221. doi:10.1136/gut.2010.213108. PMID 20650926. S2CID 18889707. Archived (PDF) from the original on 11 June 2021. Retrieved 24 September 2019.

springer.com

link.springer.com

Markham A, Goa KL (1996). "Ketotifen". Clinical Immunotherapeutics. 5 (5): 400–411. doi:10.1007/BF03259336. Archived from the original on 6 August 2024. Retrieved 17 July 2024.

trialbulletin.com

"Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness: Influenza Clinical". 30 January 2023. Archived from the original on 13 April 2024. Retrieved 13 April 2024.

ukmasto.org

"Ketotifen Update (4th December 2019)". 4 December 2019. Archived from the original on 29 November 2023. Retrieved 13 April 2024.

uspto.gov

tsdr.uspto.gov

"Trademark search - ZADITOR". USPTO. 8 April 2024. Archived from the original on 13 July 2021. Retrieved 8 April 2024.

uva.nl

pure.uva.nl

Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, et al. (September 2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome" (PDF). Gut. 59 (9): 1213–1221. doi:10.1136/gut.2010.213108. PMID 20650926. S2CID 18889707. Archived (PDF) from the original on 11 June 2021. Retrieved 24 September 2019.

web.archive.org

"Zaditor- ketotifen fumarate solution". DailyMed. 13 February 2020. Archived from the original on 11 June 2021. Retrieved 4 September 2020.
"Zaditen Product information". Health Canada. 22 October 2009. Archived from the original on 10 March 2024. Retrieved 10 March 2024.
"Zaditor Product information". Health Canada. 22 October 2009. Archived from the original on 10 March 2024. Retrieved 10 March 2024.
"Zaditen Summary of Product Characteristics (SmPC)". emc. 13 October 2020. Archived from the original on 10 March 2024. Retrieved 10 March 2024.
"Acuvue Theravision with ketotifen". DailyMed. 11 March 2022. Archived from the original on 3 December 2023.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Ketotifen Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Archived from the original on 4 June 2023. Retrieved 30 August 2024.
MacDonald G (1982). "An Overview of Ketotifen". Chest. 82 (1 Suppl): 30s – 32s. doi:10.1378/chest.82.1.30S. PMID 6806019. Archived from the original on 17 July 2024. Retrieved 17 July 2024.
Markham A, Goa KL (1996). "Ketotifen". Clinical Immunotherapeutics. 5 (5): 400–411. doi:10.1007/BF03259336. Archived from the original on 6 August 2024. Retrieved 17 July 2024.
"Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen), for ophthalmic use" (PDF). 2022. Archived (PDF) from the original on 8 March 2024. Retrieved 13 April 2024.
"Ketotifen ophthalmic Uses, Side Effects & Warnings". Archived from the original on 16 November 2023. Retrieved 16 November 2023.
"List of nationally authorised medicinal products" (PDF). European Medicines Agency. 14 June 2018. Archived (PDF) from the original on 13 April 2024. Retrieved 13 April 2024.
"Ketotifen Update (4th December 2019)". 4 December 2019. Archived from the original on 29 November 2023. Retrieved 13 April 2024.
"Ketotifen Monograph for Professionals". Archived from the original on 11 June 2021. Retrieved 16 November 2023.
"Ketotifen - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose; Drug Index; Pediatric Oncall". Pediatric Oncall. Archived from the original on 16 November 2023. Retrieved 16 November 2023.
"Ketotifen (Oral) Advanced Patient Information". Archived from the original on 2 December 2023. Retrieved 11 March 2024.
"Angle-Closure Glaucoma - Angle-Closure Glaucoma". Archived from the original on 17 May 2024. Retrieved 15 October 2024.
Ketotifen. National Institute of Child Health and Human Development. 2006. PMID 30000587. NCBI NBK501527. Archived from the original on 3 October 2023. Retrieved 22 November 2023.
"Zaditen - MIMS online". www.mims.co.uk. Archived from the original on 25 October 2020. Retrieved 2 August 2017.
Yokoyama H, Hirose M, Uematsu M, Haginoya K, Iinuma K, Kimura S (2012). "Ketotifen overdose. Toxic encephalopathy, epilepsy and mental retardation in an infant: case report". Pediatrics International. 54 (6): 963. doi:10.1111/j.1442-200X.2012.03718.x. PMID 23279031. Archived from the original on 13 April 2024. Retrieved 3 April 2024. In the present case, a 4-month-old boy was administered ketotifen at 5 times the recommended dose, and he showed mental deterioration and growth retardation. The presence of developmental deterioration strongly suggests that overdose of ketotifen induces toxic encephalopathy.
"Ketotifen 2mg Tablets, 1mg/5mL Oral Solution (product monograph)" (PDF). Archived (PDF) from the original on 18 July 2022. Retrieved 11 March 2024.
"Tablets, 1 mg ketotifen (as ketotifen hydrogen fumarate), Oral (product monograph)" (PDF). Archived (PDF) from the original on 21 February 2024. Retrieved 11 March 2024.
"Ketotifen (Oral) Advanced Patient Information". Archived from the original on 2 December 2023. Retrieved 11 March 2024.
"Ketotifen Ophthalmic: Generic, Uses, Side Effects, Dosages, Interactions, Warnings". Archived from the original on 24 February 2024. Retrieved 1 December 2023.
Lieberman P, Hernandez-Trujillo V, Lieberman J, Frew AJ (2008). "Antihistamines". Clinical Immunology. pp. 1317–1329. doi:10.1016/B978-0-323-04404-2.10089-2. ISBN 978-0-323-04404-2. Archived from the original on 24 February 2024. Retrieved 14 February 2024.
"Center for drug evaluation and research. Application no. 21-066" (PDF). Archived (PDF) from the original on 14 February 2024. Retrieved 14 February 2024.
Chiriac AM, Bousquet J, Demoly P (2017). "Principles of Allergy Diagnosis". Middleton's Allergy Essentials. pp. 117–131. doi:10.1016/B978-0-323-37579-5.00005-2. ISBN 978-0-323-37579-5. Archived from the original on 24 February 2024. Retrieved 14 February 2024.
Alapi EM, Fischer J (2006). "Table of Selected Analogue Classes". In Fischer J, Ganellin CR (eds.). Analogue-based Drug Discovery. John Wiley & Sons. p. 548. ISBN 978-3-527-60749-5. Archived from the original on 10 January 2023. Retrieved 1 August 2020.
"Ketotifen". Drugbank. 12 April 2024. Archived from the original on 6 August 2019. Retrieved 16 November 2023.
"Ketotifen Fumarate". Inxight Drugs. Bethesda MD, US: National Center for Advancing Translational Sciences (NCATS). 12 April 2024. Archived from the original on 13 April 2024. Retrieved 13 April 2024.
MacDonald G (1982). "An Overview of Ketotifen". Chest. 82 (1 Suppl): 30s – 32s. doi:10.1378/chest.82.1.30S. PMID 6806019. Archived from the original on 13 April 2024. Retrieved 13 April 2024.
"Drug Approval Package: Zaditor (Ketotifen Fumarate) NDA# 21-066". accessdata.fda.gov. 20 November 2001. Archived from the original on 8 March 2024. Retrieved 10 March 2024.
"Drug Approval Package: Acuvue Theravision with ketotifen". accessdata.fda.gov. 19 September 2022. Archived from the original on 10 March 2024. Retrieved 10 March 2024.
"Johnson & Johnson Vision Care Receives FDA Approval for Acuvue Theravision with Ketotifen – World's First and Only Drug-Eluting Contact Lens". Johnson and Johnson Vision (Press release). 2 March 2022. Archived from the original on 11 March 2024. Retrieved 10 March 2024.
"Ketotifen International". Drugs.com. Archived from the original on 11 April 2021. Retrieved 4 September 2020.
Tata (28 March 2024). "What To Know About Ketotifen (popular Brands: Ketasma And Asthafen)". MSN. Archived from the original on 13 April 2024. Retrieved 2 April 2024.
"Ketotifen (Ingredient)". Archived from the original on 2 April 2024. Retrieved 2 April 2024.
"DailyMed - ZADITOR- ketotifen fumarate solution". National Institutes of Health. 15 December 2023. Archived from the original on 11 June 2021. Retrieved 5 September 2020.
"Trademark search - ZADITOR". USPTO. 8 April 2024. Archived from the original on 13 July 2021. Retrieved 8 April 2024.
"A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Norketotifen (NKT) in the Treatment of Acute Uncomplicated Influenza-like Illness (ILI)". 25 January 2023. Archived from the original on 13 April 2024. Retrieved 13 April 2024.
"Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness: Influenza Clinical". 30 January 2023. Archived from the original on 13 April 2024. Retrieved 13 April 2024.
"Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness". 25 January 2023. Archived from the original on 20 April 2024. Retrieved 13 April 2024.
"Emergo finds midstage success in developing flu-fighter norketotifen + | Bioworld | BioWorld". Archived from the original on 13 April 2024. Retrieved 13 April 2024.
"Norketotifen in Influenza -Like Illness - Clinical Trials Registry - ICH GCP". Archived from the original on 13 April 2024. Retrieved 13 April 2024.
Asnaashari S, Delazar A, Habibi B, Vasfi R, Nahar L, Hamedeyazdan S, et al. (December 2010). "Essential oil from Citrus aurantifolia prevents ketotifen-induced weight-gain in mice". Phytotherapy Research. 24 (12): 1893–1897. doi:10.1002/ptr.3227. PMID 20623616. S2CID 8888404. Archived from the original on 28 January 2024. Retrieved 10 January 2024.
Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, et al. (September 2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome" (PDF). Gut. 59 (9): 1213–1221. doi:10.1136/gut.2010.213108. PMID 20650926. S2CID 18889707. Archived (PDF) from the original on 11 June 2021. Retrieved 24 September 2019.